Platford: Absolutely, the pandemic has certainly highlighted the vulnerabilities within the plasma-derived therapies industry. When you have a global supply chain that relies heavily on a few key countries, any disruption can have significant impacts. During the height of the pandemic, we saw challenges in plasma collection due to lockdowns and restrictions on movement. This affected our ability to meet the demand for life-saving treatments.
At Takeda, we have taken steps to increase the resilience of our supply chain. This includes diversifying our plasma collection efforts to reduce reliance on a few key countries. We are also investing in technology and automation to streamline our processes and improve efficiency. By being proactive and forward-thinking, we aim to minimize the impact of any future disruptions.
Overall, the plasma-derived therapies industry plays a crucial role in providing life-saving treatments to patients with rare and complex diseases. Takeda, under the leadership of Giles Platford, is committed to overcoming the logistical and economic challenges to ensure that patients have access to the therapies they need. Through advocacy, policy-shaping, and technological advancements, Takeda is paving the way for a more resilient and efficient plasma-derived therapies industry.
As the demand for these treatments continues to grow, it is essential that companies like Takeda continue to innovate and adapt to meet the needs of patients worldwide. By prioritizing plasma collection, process improvement, and supply chain resilience, Takeda is positioned to lead the way in the plasma-derived therapies industry for years to come.
In order to future-proof plasma therapy operations and protect against disruptions, it is crucial to diversify the sources of plasma supply. Currently, the industry heavily relies on plasma sourced from the U.S., which poses a risk in times of crisis. It is essential to seek self-sufficiency in plasma supply by exploring partnerships and alternative collection methods.
Following the global pandemic, there has been a growing interest from governments in ensuring supply-chain sovereignty, especially in critical areas like vaccines and plasma-derived therapies. By collaborating with various stakeholders and exploring different avenues, countries can work towards producing their own plasma supply, reducing dependence on a single source.
Engaging with patient advocacy groups is also vital to ensure that therapies meet real-world patient needs. At Takeda, the patient is at the forefront of decision-making processes, with a focus on patient well-being, trust-building, and reputation enhancement. By involving patients early on in research and development, defining meaningful efficacy and safety endpoints, and connecting donors to patients, Takeda strives to create a more patient-centric approach to plasma therapy.
Looking ahead, the plasma business faces both challenges and opportunities in the next decade. With significant unmet medical needs driving demand for plasma-derived therapies, the industry is poised for growth. However, meeting these needs and ensuring global access to treatments will require collaboration and innovation. Streamlining operations, driving efficiency, and reducing costs through technology advancements present an opportunity to address affordability and access challenges in plasma therapy.
By staying proactive, diversifying plasma supply sources, engaging with patient advocacy groups, and embracing technological advancements, plasma therapy operations can be future-proofed against disruptions, ensuring continued access to life-saving treatments for patients worldwide.
